Abi-Dargham, A. (2004). Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol., 7 (Suppl. 1), S1–S5.

Abi-Dargham, A. (2017). A dual hit model for dopamine in schizophrenia. Biol. Psychiatry, 81, 2–4.

Gray, J. A., and Roth, B. L. (2007). Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr. Bull., 33, 1100–1119.

Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., and Höschl, C. (2006). Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs, 20, 389–409.

Lewis, D. A., and Levitt, P. (2002). Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci., 25, 409–432.

Margolis, R. L. (2009). Neuropsychiatric disorders: The choice of antipsychotics in schizophrenia. Nat. Rev. Neurol., 5, 308–310.

Meyer, U., and Feldon, J. (2010). Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog. Neurobiol., 90, 285–326.

Papaleo, F., Lipska, B. K., and Weinberger, D. R. (2012). Mouse models of genetic effects on cognition: Relevance to schizophrenia. Neuropharmacology, 62, 1204–1220.

Rosenthal, D. (Ed.). (1963). The Genain Quadruplets: A Case Study and Theoretical Analysis of Heredity and Environment in Schizophrenia. New York: Basic Books.

Yee, B. K., and Singer, P. (2013). A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell Tissue Res., 354, 221–246.